Cargando…
Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
Parkinson’s disease (PD) is a chronic neurodegenerative disease. Type 2 diabetes mellitus (T2DM) has been identified as a risk factor for PD. Drugs originally developed for T2DM treatment such as liraglutide have shown neuroprotective effects in mouse models of PD. Cholecystokinin (CCK) is a peptide...
Autores principales: | Zhang, Zijuan, Li, Hai, Su, Yunfang, Ma, Jinlian, Yuan, Ye, Yu, Ziyang, Shi, Ming, Shao, Simai, Zhang, Zhenqiang, Hölscher, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964967/ https://www.ncbi.nlm.nih.gov/pubmed/35368248 http://dx.doi.org/10.3389/fnins.2022.814430 |
Ejemplares similares
-
e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease
por: Cataldi, Samuela, et al.
Publicado: (2016) -
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
por: Mounsey, Ross B., et al.
Publicado: (2015) -
Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
por: Singh, Shamsher, et al.
Publicado: (2017) -
Transient dystonia correlates with parkinsonism after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in nonhuman primates
por: Norris, S. A., et al.
Publicado: (2023) -
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease
por: Martin, H.L., et al.
Publicado: (2013)